

March 19, 2019

Press Release

Nichirei Biosciences Inc.

Nichirei Biosciences completes Acquisition of Medical Instrument Company in the US

Nichirei Biosciences Inc. (Representative Director & President: Masato Takenaga, head office: Tsukiji, Tokyo) announced that it has acquired Pathcom Systems Corporation, a medical instrument company in the US (location: State of California, USA, hereinafter called Pathcom) and acquisition process was completed on March 18, 2019.

Nichirei Biosciences are focusing on the business of diagnostics of cancer and companion diagnostics * to determine the treatment of patient as a core business for its growth. Pathcom acquired this time develops and manufactures medical instrument used for the cancer diagnostics and sells it in the US, Europe and China. Through this acquisition, Nichirei Biosciences will promote the diagnostics business in the United States. Nichirei Biosciences will expand our business by integrally developing, manufacturing and selling medical instrument and diagnostics, as well as their presence around the world.

* Companion Diagnostics ... An in vitro diagnostics that assist physicians in selecting effective drugs and therapies for their patients by inspecting biomarkers and genes. It is used for the purpose of improving the effectiveness and safety of a specific drug, and now several companion diagnostics are used to indication for the identification of patients suitable for molecular targeted therapies for cancer.

<About Pathcom Systems Corporation>

- (1) Company name: Pathcom Systems Corporation
- (2) Location: California, USA
- (3) Business description: Development, production and sale of medical instrument
- (4) Representative name: Glenn Takayama (CEO)
- (5) Establishment: 2005

<About Nichirei Biosciences Inc.>

Nichirei Biosciences Inc. is an operating company spun off in April 2005 following the shift to the holding company structure of the Nichirei Group. Nichirei entered the

bioscience business from the time of importing serum of bovine used for culturing cells from the United States etc. in the 1980's. Nichirei Biosciences Inc. currently produces and sells immunohistochemistry products based on immune related technology, various rapid diagnostics kits including influenza virus, production and sale of functional materials of cosmetics and health foods, and sells animal serums and media related to cell culture.

<Impact on business results>

The impact on this consolidated business results for the fiscal year ending March 2019 will be minor.

<Inquiries concerning this matter>

Nichirei Biosciences Inc. /TEL +81-3-3248-2208